A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of
 single oral doses of daclatasvir in subjects with chronic hepatitis C infection
Key Inclusion Criteria:

 -  Chronically infected with hepatitis C virus genotype 1

 -  Treatment naive or treatment non-responders or treatment intolerant; and not
 co-infected with HIV or hepatitis B virus

 -  Hepatitis C virus RNA viral load of ≥ 10*5* IU/mL

 -  BMI 18 to 35 kg/m²

 Key Exclusion Criteria:

 -  Any significant acute or chronic medical illness which is not stable or is not
 controlled with medication and not consistent with hepatitis C virus infection

 -  Major surgery within 4 weeks of study drug administration and any gastrointestinal
 surgery that could impact the absorption of study drug